Ruconest (Santarus, Inc.)


Welcome to the PulseAid listing for the Ruconest drug offered from Santarus, Inc.. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Santarus, Inc.
NON-PROPRIETARY NAME: c1 esterase inhibitor recombinant
SUBSTANCE NAME: CONESTAT ALFA
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS:
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION, POWDER, FOR SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2014-09-22
END MARKETING DATE: 0000-00-00


Ruconest HUMAN PRESCRIPTION DRUG Details:

Item DescriptionRuconest from Santarus, Inc.
LABELER NAME: Santarus, Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 2100(U/1)
START MARKETING DATE: 2014-09-22
END MARKETING DATE: 0000-00-00
PRODUCT ID: 68012-350_3c153275-2fb0-4620-89a5-846d3a70ad96
PRODUCT NDC: 68012-350
APPLICATION NUMBER: BLA125495

Other CONESTAT ALFA Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Santarus, Inc.Ruconest
Tjoapack Netherlands BVRuconest